News For SNY From The Last 14 Days Check below for free stories on SNY the last two weeks.
There are 12 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 04:58 EDT |  | SNY |
| theflyonthewall.com: | Osiris Therapeutics provides update regarding the Genzyme/Sanofi relationship |
 Subscribe for More Information :theflyonthewall.com |
|
|
February 8, 2012
|
| 11:05 EDT | | SNY |
| theflyonthewall.com: | Genzyme says data show sustained, continued improvement with eliglustat tartrate | | Genzyme, a Sanofi company (SNY), announced four-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including markers of bone disease, at the four-year timepoint. The results will be presented for the first time this week at the Lysosomal Disease Network WORLD Symposium in San Diego, Calif. Genzyme has also fully enrolled all three phase 3 trials for the oral therapy. :theflyonthewall.com |
| | 06:21 EDT |  | SNY |
| theflyonthewall.com: | Sanofi reports Q4 EPS EUR1.56, up 9.2% YoY at constant exchange rates | | Reports Q4 revenue EUR8.51B, up 8.8% YoY :theflyonthewall.com |
| | 06:13 EDT | | SNY |
| theflyonthewall.com: | Sanofi CEO 2012 sees 2012 business EPS 12-15% lower than 2011 | | :theflyonthewall.com |
| | 06:11 EDT | | SNY |
| theflyonthewall.com: | Sanofi CEO expects sales growth of at least 5% over 2012-2015 | | :theflyonthewall.com |
| | 05:32 EDT | | SNY |
| theflyonthewall.com: | Sanofi, Bristol-Myers collect damages in Plavix patent litigation with Apotex | | Sanofi (SNY) and Bristol-Myers Squibb (BMY) announced that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix, or clopidogrel bisulfate, patent infringement case against Apotex. This payment, which follows the decision of the U.S. Court of Appeals for the Federal Circuit in October 2011 upholding the payment of damages to the companies by Apotex, represents the final phase of the Plavix patent litigation between the companies and Apotex, which was initiated on March 21, 2002. Sanofi and Bristol-Myers Squibb were also awarded $1,258,682 in post-judgment interest and $900,000 in costs in addition to the damages award. :theflyonthewall.com |
|
|
February 7, 2012
|
| 14:06 EDT | | SNY |
| | 13:45 EDT |  | SNY |
| theflyonthewall.com: | Judge rules for FDA, against Sanofi, in generic Lovenox appeal, Bloomberg says |
Subscribe for More Information :theflyonthewall.com |
| | 07:34 EDT | | SNY |
|
|
February 6, 2012
|
| 08:10 EDT | | SNY |
| theflyonthewall.com: | Valeant Pharma completes divestiture of generic dermatology products to Mylan | | Valeant Pharmaceuticals (VRX) announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel, or IDP-111, a generic version of Benzaclin, and 5% fluorouracil cream, 5-FU, an authorized generic of Efudex, to Mylan (MYL). This action was required under the consent order issued by the Federal Trade Commission, or FTC, as part of the acquisition of Dermik, a dermatology unit of Sanofi (SNY), which was completed in December 2011. :theflyonthewall.com |
|
|
February 1, 2012
|
| 08:52 EDT |  | SNY |
|
|
January 29, 2012
|
| 12:26 EDT | | SNY |
|
|
|
